Childhood chronic myeloid leukemia in accelerated phase with EVI1 positive: report of one case and review of literature
Q4 Medicine
引用次数: 0
Abstract
目的 提高对EVI1基因阳性的儿童慢性粒细胞白血病加速期（CML-AP）的认识。 方法 回顾性分析青岛市妇女儿童医院2019年1月收治的1例EVI1基因阳性的儿童CML-AP患者的临床资料，并复习相关文献。 结果 患儿，男性，14岁，确诊后，加用国产伊马替尼联合小剂量化疗方案，达血液学完全缓解。BCR-ABL p210定量降至4.66%，EVI1定量降至正常（0.01%）。 结论 儿童CML-AP罕见，临床特征主要为白细胞计数明显升高和巨脾。国产伊马替尼联合小剂量化疗方案对EVI1基因阳性的儿童CML-AP治疗有效，远期疗效尚需密切随访。EVI1阳性儿童慢性粒细胞白血病加速期1例报告及文献复习
Objective: To improve understanding of the accelerated phase of chronic myeloid leukemia (CML-AP) in children with EVI1 gene positivity. Method: A retrospective analysis was conducted on the clinical data of one EVI1 gene positive child CML-AP patient admitted to Qingdao Women and Children's Hospital in January 2019, and relevant literature was reviewed. The patient, male, 14 years old, was diagnosed and received a combination of domestic imatinib and low-dose chemotherapy, achieving complete hematological remission. The quantification of BCR-ABL p210 decreased to 4.66%, and the quantification of EVI1 decreased to normal (0.01%). Conclusion: CML-AP in children is rare, and its clinical features mainly include a significant increase in white blood cell count and splenomegaly. The combination of domestic imatinib and low-dose chemotherapy is effective in the treatment of CML-AP in children with EVI1 gene positivity, but the long-term efficacy still needs close follow-up.
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
